[Effectiveness of prestarium in the treatment of chronic cor pulmonale].
To study efficiency and safety of application of perindopril (prestarium) in patients with chronic cor pulmonale (CCP). The trial included 26 patients with chronic obstructive pulmonary disease complicated with CCP and cardiac failure of NYHA class II-III. The study group of 16 patients received perindopril 2-4 mg/day for 3 months. 10 controls received routine therapy. All the patients were examined before the treatment and 3 months after it using physical examination, echocardiography, Doppler echocardiography, 24-h Holter ECG monitoring, assessment of potassium and creatinine in the serum, quality of life. The treatment decreased functional class of cardiac failure and mean pulmonary arterial pressure, lowered malignant arrhythmia frequency, improved quality of life and intracardiac hemodynamics, inhibited right ventricular remodelling. Perindopril is well tolerated and safe efficient medicine in patients with decompensated CCP.